Virios Therapeutics (VIRI) Issues Shareholder Letter

Go back to Virios Therapeutics (VIRI) Issues Shareholder Letter

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

February 28, 2024 9:16 AM EST

ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the Company), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (FM)... More